AstraZeneca Sept. 10 announced that the Food and Drug Administration has approved the 500 milligram dose of Faslodex (fulvestrant injection), replacing the previously approved monthly dose of 250 mg.
Faslodex is indicated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, the company said.
AstraZeneca said the 500 mg dosing regimen can improve progression free survival compared with the 250 mg dose.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.